Cargando…

Synergistic immunotoxin-paclitaxel combination against lymphoma

Detalles Bibliográficos
Autor principal:	Müller, Fabian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509450/ https://www.ncbi.nlm.nih.gov/pubmed/28637932 http://dx.doi.org/10.18632/aging.101251

Ejemplares similares

Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies
por: Müller, Fabian, et al.
Publicado: (2017)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
por: Pegna, Guillaume Joe, et al.
Publicado: (2022)

Immunotoxins: From Design to Clinical Application
por: Kreitman, Robert J., et al.
Publicado: (2021)

Toxin and Immunotoxin Based Therapeutic Approaches
por: Bortolotti, Massimo, et al.
Publicado: (2022)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes
por: Kolyvas, Emily, et al.
Publicado: (2016)

Synergistic SNGI-TKI combination against LSCs
por: Jiang, Xiaoyan
Publicado: (2017)

Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma
por: Risberg, Karianne, et al.
Publicado: (2011)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
por: Novakovic, Barbara Jezersek
Publicado: (2015)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect
por: Heiat, Mohammad, et al.
Publicado: (2021)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Cyclooxygenase-2 mediated synergistic effect of ursolic acid in combination with paclitaxel against human gastric carcinoma
por: Xu, Xian, et al.
Publicado: (2017)

Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells
por: Kyakulaga, Al Hassan, et al.
Publicado: (2020)

Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells
por: Wang, Chihuei, et al.
Publicado: (2015)

In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer
por: Michalska, Marta, et al.
Publicado: (2016)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2019)

Bispecific human IL2‐CCR4 immunotoxin targets human cutaneous T‐cell lymphoma
por: Wang, Haoyu, et al.
Publicado: (2020)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

Production and Evaluation of an Avian IgY Immunotoxin against CD133+ for Treatment of Carcinogenic Stem Cells in Malignant Glioma: IgY Immunotoxin for the Treatment of Glioblastoma
por: Chavez-Cortez, Elda-Georgina, et al.
Publicado: (2019)

Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells
por: Zhang, Xin, et al.
Publicado: (2022)

Clinical targeting recombinant immunotoxins for cancer therapy
por: Li, Meng, et al.
Publicado: (2017)

Systemic immunotoxin therapy of cancer: advances and prospects.
por: Wawrzynczak, E. J.
Publicado: (1991)

Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary
por: Tortorella, Lori L., et al.
Publicado: (2012)

Immunotoxins: A Review of Their Use in Cancer Treatment
por: Aruna, G
Publicado: (2006)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Development of Recombinant Immunotoxins for Hairy Cell Leukemia
por: Kreitman, Robert J., et al.
Publicado: (2020)

Antibody-Based Immunotoxins for Colorectal Cancer Therapy
por: Sanz, Laura, et al.
Publicado: (2021)

Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain
Publicado: (1984)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells
por: Jiménez-Guerrero, Rocío, et al.
Publicado: (2018)

Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin
por: Flavell, D J, et al.
Publicado: (2001)

In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma
por: Yu, YanXin, et al.
Publicado: (2017)

Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β–Expressing Macrophages
por: Furusho, Yuko, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7jj77cm6g2gejo3kuvm3m3jvad